Abstract
Abstract Aim It is established that axillary dissection (AD) can be safely avoided in breast cancer patients with a negative sentinel node (SN). In the present study we assessed whether the rate of axillary disease was sufficiently low on long term follow-up to consolidate the policy of AD avoidance. Methods We retrospectively analysed data on 5262 consecutive primary breast cancer patients with clinically negative axilla and negative SN, treated from 1996 to 2006, who did not receive AD. We used univariate and multivariate analyses to assess the influence of patient and tumour characteristics on first events and survival. The primary endpoint was the development of axillary disease as first event. Results After a median follow-up of 7.0 years (interquartile range 5.4-8.9 years) survival for the series was high (91.3%; 95% CI 90.3-92.3 at 10 years) and only 91 (1.7%) patients developed axillary disease as first event. Axillary disease was significantly more frequent in patients with the following characteristics: 1 cm, multifocality/multicentricity, G3, ductal histotype, Ki67 ≥ 30%, peritumoral vascular invasion, luminal B-like subtype, HER2 positivity, mastectomy, and not receiving radiotherapy. Conclusion Long-term follow-up of our large series confirms that axillary metastasis is infrequent when AD is omitted in SN-negative breast cancer patients, and has low impact on overall survival.
| Original language | English |
|---|---|
| Article number | 3883 |
| Pages (from-to) | 1203-1208 |
| Number of pages | 6 |
| Journal | European Journal of Surgical Oncology |
| Volume | 40 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 1 2014 |
Fingerprint
Keywords
- Axillary disease
- Axillary dissection
- Breast cancer
- Sentinel node biopsy
ASJC Scopus subject areas
- Oncology
- Surgery
- Medicine(all)
Cite this
Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. / Galimberti, V.; Manika, A.; Maisonneuve, P.; Corso, G.; Salazar Moltrasio, L.; Intra, M.; Gentilini, O.; Veronesi, P.; Pagani, G.; Rossi, E.; Bottiglieri, L.; Viale, G.; Rotmensz, N.; De Cicco, C.; Grana, C. M.; Sangalli, C.; Luini, A.
In: European Journal of Surgical Oncology, Vol. 40, No. 10, 3883, 01.10.2014, p. 1203-1208.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease
AU - Galimberti, V.
AU - Manika, A.
AU - Maisonneuve, P.
AU - Corso, G.
AU - Salazar Moltrasio, L.
AU - Intra, M.
AU - Gentilini, O.
AU - Veronesi, P.
AU - Pagani, G.
AU - Rossi, E.
AU - Bottiglieri, L.
AU - Viale, G.
AU - Rotmensz, N.
AU - De Cicco, C.
AU - Grana, C. M.
AU - Sangalli, C.
AU - Luini, A.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Abstract Aim It is established that axillary dissection (AD) can be safely avoided in breast cancer patients with a negative sentinel node (SN). In the present study we assessed whether the rate of axillary disease was sufficiently low on long term follow-up to consolidate the policy of AD avoidance. Methods We retrospectively analysed data on 5262 consecutive primary breast cancer patients with clinically negative axilla and negative SN, treated from 1996 to 2006, who did not receive AD. We used univariate and multivariate analyses to assess the influence of patient and tumour characteristics on first events and survival. The primary endpoint was the development of axillary disease as first event. Results After a median follow-up of 7.0 years (interquartile range 5.4-8.9 years) survival for the series was high (91.3%; 95% CI 90.3-92.3 at 10 years) and only 91 (1.7%) patients developed axillary disease as first event. Axillary disease was significantly more frequent in patients with the following characteristics: 1 cm, multifocality/multicentricity, G3, ductal histotype, Ki67 ≥ 30%, peritumoral vascular invasion, luminal B-like subtype, HER2 positivity, mastectomy, and not receiving radiotherapy. Conclusion Long-term follow-up of our large series confirms that axillary metastasis is infrequent when AD is omitted in SN-negative breast cancer patients, and has low impact on overall survival.
AB - Abstract Aim It is established that axillary dissection (AD) can be safely avoided in breast cancer patients with a negative sentinel node (SN). In the present study we assessed whether the rate of axillary disease was sufficiently low on long term follow-up to consolidate the policy of AD avoidance. Methods We retrospectively analysed data on 5262 consecutive primary breast cancer patients with clinically negative axilla and negative SN, treated from 1996 to 2006, who did not receive AD. We used univariate and multivariate analyses to assess the influence of patient and tumour characteristics on first events and survival. The primary endpoint was the development of axillary disease as first event. Results After a median follow-up of 7.0 years (interquartile range 5.4-8.9 years) survival for the series was high (91.3%; 95% CI 90.3-92.3 at 10 years) and only 91 (1.7%) patients developed axillary disease as first event. Axillary disease was significantly more frequent in patients with the following characteristics: 1 cm, multifocality/multicentricity, G3, ductal histotype, Ki67 ≥ 30%, peritumoral vascular invasion, luminal B-like subtype, HER2 positivity, mastectomy, and not receiving radiotherapy. Conclusion Long-term follow-up of our large series confirms that axillary metastasis is infrequent when AD is omitted in SN-negative breast cancer patients, and has low impact on overall survival.
KW - Axillary disease
KW - Axillary dissection
KW - Breast cancer
KW - Sentinel node biopsy
UR - http://www.scopus.com/inward/record.url?scp=84925222995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925222995&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2014.07.041
DO - 10.1016/j.ejso.2014.07.041
M3 - Article
VL - 40
SP - 1203
EP - 1208
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
SN - 0748-7983
IS - 10
M1 - 3883
ER -